TD Asset Management Inc raised its position in Abivax SA Sponsored ADR (NASDAQ:ABVX – Free Report) by 37.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 63,902 shares of the company’s stock after purchasing an additional 17,416 shares during the quarter. TD Asset Management Inc owned 0.08% of Abivax worth $8,618,000 as of its most recent SEC filing.
Other large investors have also recently bought and sold shares of the company. EverSource Wealth Advisors LLC raised its position in Abivax by 4,612.5% in the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after purchasing an additional 369 shares during the last quarter. WPG Advisers LLC raised its position in Abivax by 125.9% in the fourth quarter. WPG Advisers LLC now owns 454 shares of the company’s stock valued at $61,000 after purchasing an additional 253 shares during the last quarter. Union Bancaire Privee UBP SA bought a new position in Abivax in the fourth quarter valued at about $67,000. Hantz Financial Services Inc. bought a new position in Abivax in the third quarter valued at about $52,000. Finally, Assetmark Inc. bought a new position in Abivax in the fourth quarter valued at about $84,000. 47.91% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Several equities analysts have commented on the company. Morgan Stanley dropped their target price on Abivax from $145.00 to $132.00 and set an “overweight” rating for the company in a research report on Tuesday, June 2nd. Wedbush upgraded Abivax from an “underperform” rating to a “neutral” rating and dropped their target price for the company from $110.00 to $90.00 in a research report on Tuesday, June 2nd. Truist Financial decreased their price target on Abivax from $140.00 to $135.00 and set a “buy” rating for the company in a research note on Tuesday, June 2nd. Wall Street Zen raised Abivax from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. Finally, Citizens Jmp increased their price target on Abivax from $131.00 to $187.00 and gave the company a “market outperform” rating in a research note on Tuesday, June 2nd. Twelve equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $130.08.
Abivax Trading Up 1.2%
Shares of ABVX stock opened at $102.72 on Wednesday. The stock has a market cap of $8.19 billion, a price-to-earnings ratio of -19.72 and a beta of 0.69. The stock has a 50-day moving average of $116.66 and a 200-day moving average of $119.58. Abivax SA Sponsored ADR has a 1-year low of $5.69 and a 1-year high of $148.83.
Abivax (NASDAQ:ABVX – Get Free Report) last issued its quarterly earnings results on Friday, May 22nd. The company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.94) by $0.23. The company had revenue of $1.56 million during the quarter, compared to analyst estimates of $0.40 million. Sell-side analysts forecast that Abivax SA Sponsored ADR will post -3.4 earnings per share for the current year.
About Abivax
Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.
Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.
Featured Stories
- Five stocks we like better than Abivax
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
- Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer
Want to see what other hedge funds are holding ABVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abivax SA Sponsored ADR (NASDAQ:ABVX – Free Report).
Receive News & Ratings for Abivax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abivax and related companies with MarketBeat.com's FREE daily email newsletter.
